How should I initially manage a hemodynamically stable adult with atrial fibrillation and a rapid ventricular response (ventricular rate >100 bpm)?

Management of Hemodynamically Stable Atrial Fibrillation with Rapid Ventricular Response

For a hemodynamically stable adult with atrial fibrillation and rapid ventricular response (>100 bpm), immediately initiate intravenous rate control with either a β-blocker (metoprolol 2.5–5 mg IV over 2 minutes) or a non-dihydropyridine calcium-channel blocker (diltiazem 0.25 mg/kg IV over 2 minutes), while simultaneously assessing stroke risk and initiating appropriate anticoagulation. 1, 2, 3

Immediate Assessment

Confirm Hemodynamic Stability

• Unstable patients require immediate synchronized electrical cardioversion (≥200 J biphasic) without waiting for anticoagulation. Instability is defined by systolic blood pressure <90 mmHg, altered mental status, acute pulmonary edema, ongoing chest pain, or cardiogenic shock. 1, 2, 4
• Stable patients proceed with pharmacologic rate control. 1, 2

Obtain 12-Lead ECG

• Document the rhythm, assess ventricular rate, measure QRS duration, and identify any pre-excitation (delta waves suggesting Wolff-Parkinson-White syndrome). 2, 3
• In Wolff-Parkinson-White syndrome with pre-excited AF, avoid all AV-nodal blockers (β-blockers, calcium-channel blockers, digoxin, adenosine, amiodarone) as they can precipitate ventricular fibrillation; use IV procainamide or ibutilide instead, or proceed directly to cardioversion. 1, 2, 4

Determine Left Ventricular Ejection Fraction

• Obtain a transthoracic echocardiogram before selecting rate-control agents to determine whether LVEF is preserved (>40%) or reduced (≤40%), as this dictates drug choice. 1, 2, 3

Rate-Control Strategy

Patients with Preserved LVEF (>40%)

Either intravenous β-blocker or non-dihydropyridine calcium-channel blocker is appropriate as first-line therapy; both are equally effective. 1, 2, 3

Metoprolol Regimen

• Administer metoprolol 2.5–5 mg IV bolus over 2 minutes; repeat every 5 minutes up to a total of 15 mg. Onset of action is approximately 5 minutes. 1, 2
• Transition to oral metoprolol succinate 50–100 mg once daily after acute control is achieved. 2, 3

Diltiazem Regimen

• Administer diltiazem 0.25 mg/kg IV (approximately 15–20 mg) over 2 minutes. 1, 2, 5
• If needed, give a second bolus of 0.35 mg/kg, followed by continuous infusion of 5–15 mg/h. Onset is 2–7 minutes. 1, 2
• Head-to-head studies show diltiazem achieves rate control faster than metoprolol, with comparable safety. 5

Patients with Reduced LVEF (≤40%) or Heart Failure

Use only β-blockers (bisoprolol, carvedilol, or long-acting metoprolol) and/or digoxin; non-dihydropyridine calcium-channel blockers are contraindicated because of negative inotropic effects that may precipitate hemodynamic collapse. 1, 2, 3

β-Blocker Regimen

• Administer metoprolol 2.5–5 mg IV bolus over 2 minutes, repeat as needed. 1, 2
• β-blockers are preferred because they have demonstrated mortality benefit in heart failure with reduced ejection fraction. 2

Digoxin Regimen

• Administer digoxin 0.25 mg IV (may repeat to a cumulative 1.5 mg/24 hours). 1, 2, 6
• Digoxin does not improve survival but enhances rate control when combined with a β-blocker, especially when hypotension limits β-blocker use. 2
• Digoxin alone is ineffective for acute rate control in AF with RVR, especially during sympathetic surges; it should not be used as monotherapy. 1, 2, 3, 7

Heart-Rate Targets

• Aim for an initial lenient resting heart rate <110 bpm. 1, 2, 3
• Pursue a stricter target (<80 bpm) only if symptoms persist despite achieving the lenient goal. 1, 2
• Assess heart rate during exertion, not solely at rest, because many patients have inadequate control during activity despite acceptable resting rates. 1, 2, 3

Escalation to Combination Therapy

• If adequate rate control is not achieved within 4–7 days of optimal monotherapy, add digoxin (0.0625–0.25 mg PO daily) to the β-blocker or calcium-channel blocker. 1, 2, 3
• Combination therapy provides superior control at rest and during exercise compared with either agent alone. 1, 2, 3
• Monitor closely for bradycardia when combining AV-nodal blockers. 2
• Never combine β-blocker with calcium-channel blocker except under specialist supervision due to risk of severe bradycardia and heart block. 2

Anticoagulation Strategy

CHA₂DS₂-VASc Scoring

• Calculate the CHA₂DS₂-VASc score immediately: congestive heart failure (1 point), hypertension (1), age ≥75 years (2), diabetes (1), stroke/TIA/thromboembolism (2), vascular disease (1), age 65–74 (1), female sex (1). 1, 2, 3

Oral Anticoagulation

• Initiate oral anticoagulation for all patients with a score ≥2 (men) or ≥3 (women). 1, 2, 3
• Direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) are preferred over warfarin because of lower intracranial-hemorrhage risk and predictable pharmacokinetics. 1, 2, 3
• Warfarin is reserved for mechanical heart valves, moderate-to-severe mitral stenosis, or end-stage renal disease (CrCl <15 mL/min or dialysis). Target INR 2.0–3.0; check weekly during initiation, monthly once stable. 1, 2, 3

Pre-Cardioversion Anticoagulation

• For AF >48 hours or unknown duration, provide therapeutic anticoagulation for ≥3 weeks before elective cardioversion and ≥4 weeks after. 1, 2, 3
• Alternatively, perform transesophageal echocardiography; if no left-atrial thrombus is seen, cardioversion may proceed after initiating heparin. 1, 2
• Anticoagulation must be continued after successful cardioversion when CHA₂DS₂-VASc ≥2, as stroke risk is independent of rhythm status. 1, 2, 3

Special Populations

Chronic Obstructive Pulmonary Disease or Active Bronchospasm

• Prefer non-dihydropyridine calcium-channel blockers (diltiazem or verapamil); avoid β-blockers. 1, 2, 3

Thyrotoxicosis

• β-blocker is the preferred agent for ventricular-rate control unless contraindicated. 2, 3

Wolff-Parkinson-White Syndrome with Pre-Excited AF

• If unstable: immediate DC cardioversion. 1, 2, 4
• If stable: IV procainamide or ibutilide. 1, 2, 4
• β-blockers, calcium-channel blockers, digoxin, adenosine, and amiodarone are contraindicated because they can precipitate ventricular fibrillation. 1, 2, 4

Rhythm-Control Considerations

• Rhythm control is not mandatory when rate control and anticoagulation are adequate; however, consider it for patients who remain symptomatic despite optimal rate control, younger patients (<65 years) with new-onset AF, those with rate-related cardiomyopathy, or hemodynamically unstable presentations. 1, 2, 3
• Evidence shows that rate control plus anticoagulation is as effective as rhythm control for reducing mortality and cardiovascular events, with fewer adverse effects and hospitalizations. 1, 2, 3

Common Pitfalls to Avoid

• Do not use digoxin alone for acute rate control; it is ineffective during sympathetic surges. 1, 2, 3, 7
• Do not use non-dihydropyridine calcium-channel blockers in patients with LVEF ≤40% or decompensated heart failure. 1, 2, 3
• Do not rely solely on resting heart rate; always assess rate during exertion. 1, 2
• Do not discontinue anticoagulation after cardioversion when CHA₂DS₂-VASc ≥2; 72% of strokes in the AFFIRM trial occurred when anticoagulation was stopped or INR was subtherapeutic. 2, 3
• Do not combine β-blocker with calcium-channel blocker without specialist supervision. 2
• Do not use aspirin alone for stroke prevention; oral anticoagulants are superior. 2, 3